Last Updated: September 26, 2026

Details for New Drug Application (NDA): 217006

✉ Email this page to a colleague

NDA 217006 describes ABILIFY ASIMTUFII, which is a drug marketed by Otsuka and is included in one NDA. It is available from one supplier. There are four patents protecting this drug. Additional details are available on the ABILIFY ASIMTUFII profile page.

The generic ingredient in ABILIFY ASIMTUFII is aripiprazole. There is one drug master file entry for this compound. Fifty suppliers are listed for this compound. Additional details are available on the aripiprazole profile page.

Summary for 217006

Tradename:	ABILIFY ASIMTUFII
Applicant:	Otsuka
Ingredient:	aripiprazole
Patents:	4

Pharmacology for NDA: 217006

Medical Subject Heading (MeSH) Categories for 217006

Antipsychotic Agents

Suppliers and Packaging for NDA: 217006

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
ABILIFY ASIMTUFII	aripiprazole	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	217006	NDA	Otsuka America Pharmaceutical, Inc	59148-102	59148-102-80	1 SYRINGE in 1 CARTON (59148-102-80) / 2.4 mL in 1 SYRINGE
ABILIFY ASIMTUFII	aripiprazole	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	217006	NDA	Otsuka America Pharmaceutical, Inc	59148-114	59148-114-80	1 SYRINGE in 1 CARTON (59148-114-80) / 3.2 mL in 1 SYRINGE

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR			Strength	720MG/2.4ML (300MG/ML)
Approval Date:	Apr 27, 2023	TE:		RLD:	Yes
Patent:	⤷ Start Trial	Patent Expiration:	Apr 23, 2033	Product Flag?	Y	Substance Flag?		Delist Request?
Patented Use:	MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER
Patent:	⤷ Start Trial	Patent Expiration:	Apr 23, 2033	Product Flag?	Y	Substance Flag?		Delist Request?
Patented Use:	TREATMENT OF SCHIZOPHRENIA
Patent:	⤷ Start Trial	Patent Expiration:	Apr 23, 2033	Product Flag?	Y	Substance Flag?		Delist Request?
Patented Use:	MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER

Expired US Patents for NDA 217006

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Otsuka	ABILIFY ASIMTUFII	aripiprazole	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	217006-001	Apr 27, 2023	⤷ Start Trial	⤷ Start Trial
Otsuka	ABILIFY ASIMTUFII	aripiprazole	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	217006-002	Apr 27, 2023	⤷ Start Trial	⤷ Start Trial
Otsuka	ABILIFY ASIMTUFII	aripiprazole	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	217006-001	Apr 27, 2023	⤷ Start Trial	⤷ Start Trial
Otsuka	ABILIFY ASIMTUFII	aripiprazole	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	217006-001	Apr 27, 2023	⤷ Start Trial	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.